Risk factors
Biohaven (BHVN) risk factors
Item 1A of every Biohaven Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors61 risks6 new7 reworded
Biohaven secured a $250 million note purchase agreement with Oberland Capital Management.
Filed Mar 02, 2026 - FY2024 10-K risk factors55 risks
Biohaven faces substantial operating losses, with a net loss of $846.4 million in 2024 and no product revenues to date. The company relies heavily on third-party suppliers, clinical trial outcomes, and patent protection for candidates like troriluzole and taldefgrobep alfa.
Filed Mar 03, 2025